# The Cigna Group (CI) — Investment Thesis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Tier:** Free primer (steps 1 & 3 of 19)  
**Sibling pages:** /stocks/CI/financials · /stocks/CI/memo

> This page shows the free thesis context (business model + recent catalysts).
> The full investment thesis (moat analysis, DCF, scenarios, risk register) is available
> via GET /api/v1/research/CI/memo ($2.00, Bearer token).

## Business Model

---
ticker: CI
step: 01
generated: 2026-05-12
source: quick-research
---

### The Cigna Group (CI) — Business Overview

#### Business Description
The Cigna Group is a US health-services holding company with two principal divisions: **Evernorth Health Services** (the pharmacy benefits manager Express Scripts, specialty pharmacy Accredo, and a growing care-services portfolio) and **Cigna Healthcare** (commercial health insurance for employers and select individual markets). After the March 2025 sale of its Medicare Advantage and Medicare Part D businesses to Health Care Service Corporation (HCSC) for $3.7B, Cigna is now focused on commercial health benefits + pharmacy services — a deliberate exit from the volatile MA market that has hurt peers.

#### Revenue Model
Two reporting segments:
- **Evernorth Health Services (~83% of revenue, ~60% of profit):** Express Scripts PBM (largest in US by volume, surpassed CVS Caremark in 2025), Accredo specialty pharmacy, EviCore medical-benefits management, and care-services / digital-care platforms. FY2025 revenue $234.95B (vs. $202.2B in 2024) on 123.6M pharmacy customers (up from 118.3M).
- **Cigna Healthcare (~17% of revenue, ~40% of profit):** Commercial group medical insurance (employer-sponsored fully-insured + ASO), International Health, dental, behavioral health, and select individual plans. FY2025 revenue $47.2B (down from $52.9B in 2024 due to MA divestiture).

The strategic narrative is shifting Evernorth toward a more transparent, fee-based pharmacy model: by 2028 Express Scripts will pass through 100% of negotiated drug rebates to clients (currently >95% passed through; retained rebates <10% of Evernorth's adjusted pre-tax earnings).

#### Products & Services
**Evernorth (pharmacy & specialty services):**
- **Express Scripts** — largest US PBM by volume; formulary management, drug rebate negotiation, pharmacy network, mail-order, claims processing
- **Accredo** — specialty pharmacy for high-cost biologics, oncology, rare disease, complex therapies
- **EviCore by Evernorth** — medical-benefits management / utilization review
- **Cigna Pharmacy Solutions, CuraScript SD, ESI**
- **Evernorth Care Group** — direct primary care, behavioral health, virtual care
- **MDLIVE** — telehealth platform
- **New Era transparent pharmacy model** — rebate-free fee-based PBM (rolling out 2026–2028)

**Cigna Healthcare (insurance products):**
- Employer-sponsored group medical (commercial fully-insured + ASO)
- Behavioral health & EAP
- Cigna Dental
- Cigna International (employer / expatriate)
- Individual & family commercial plans (limited footprint)
- Vision, supplemental products

#### Customer Base & Go-to-Market
**Evernorth customers:**
- **Health plans:** Cigna Healthcare itself plus large external clients — Anthem (Elevance Health) is the largest external PBM client, plus dozens of regional plans, government plans, union/labor funds.
- **Employers:** Direct PBM contracts with Fortune 500 and middle-market employers, often paired with insurance products from a competing insurer.
- **Government / public health:** Express Scripts serves military (TRICARE), federal employee health plans.

**Cigna Healthcare customers:**
- **Employers:** ~16M+ commercial members, predominantly mid- to large-employer market.
- **Brokers:** Distribution heavily via benefits consultants / brokers.
- **Geographic mix:** US commercial-heavy; international expat business adds modest diversification.

The Anthem-Express Scripts contract (the largest external PBM relationship in US healthcare) is the single largest customer concentration risk — typically modeled as a few hundred basis points of Evernorth revenue.

#### Competitive Position
The Cigna Group operates the #1 PBM in the US (Express Scripts surpassed CVS Caremark in 2025 by volume) and is the #3 commercial health insurer by membership behind UnitedHealth and Elevance Health. Key competitive advantages: (1) **Scale in pharmacy services** — Express Scripts' negotiating leverage with manufacturers + Accredo's specialty distribution moat support gross-margin durability, (2) **Anthem partnership** — the multi-decade PBM contract creates a sticky revenue base, (3) **Cleaner portfolio post-MA divestiture** — having sold off MA and Part D, Cigna avoids the medical-loss-ratio chaos that has hurt UnitedHealth, Humana, and Elevance through 2024/2025, (4) **Evernorth growth engine** — the segment is growing materially faster than legacy commercial insurance, (5) **Care services optionality** — the build-out of Evernorth Care Group, virtual care, and behavioral health provides additional growth pillars. Key challenges: PBM regulatory pressure (FTC, Congress, state-level mandates); rebate-free model transition will compress 2026–2028 pharmacy profits even as it builds long-term trust; competitive pressure from CVS Caremark and OptumRx; concentration risk on the Anthem relationship; valuation discount to UNH despite cleaner book.

#### Key Facts
- Founded: 1792 (Insurance Company of North America); merged with CIGNA Corporation 1982; combined with Express Scripts 2018
- Headquarters: Bloomfield, CT
- Employees: ~71,000
- Exchange: NYSE
- Sector / Industry: Health Care / Health Care Plans
- Market Cap: ~$85B (May 2026)
- Pharmacy customers: 123.6M (as of Dec 31, 2025)
- Insurance medical members: ~16M

## Recent Catalysts

---
ticker: CI
step: 12
generated: 2026-05-12
source: quick-research
---

### The Cigna Group (CI) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **Clean book post-MA divestiture** — Cigna sold its Medicare Advantage and Medicare Part D businesses to HCSC for $3.7B in March 2025, deliberately exiting a segment where UnitedHealth, Humana, and Elevance are facing crippling medical-loss-ratio pressure. Cigna avoids the regulatory and reimbursement chaos that has compressed peer multiples — a structurally simpler story than at any time in the last decade.

2. **Evernorth growing 16%+ as Express Scripts overtakes CVS as #1 PBM** — Express Scripts became the largest US PBM by volume in 2025, with 123.6M pharmacy customers (+4.5% YoY) and Evernorth revenue +16% to $235B. The combination of scale, the Anthem multi-decade contract, and Accredo's specialty pharmacy moat support durable mid-teens revenue growth.

3. **FTC settlement (Feb 2026) resolves the regulatory overhang with no monetary fines** — Settlement requires structural reforms (eliminate spread pricing, decouple rebates from list price, relocate Ascent GPO to US, 10-year monitoring, cost-plus reimbursement for small independents). Most reforms were already underway via Cigna's own rebate-free pivot. The lack of fines + the structural certainty re-rate the stock relative to peers still facing PBM litigation.

4. **Aggressive capital return + valuation re-rate optionality** — Cigna repurchased 11.9M shares in 2025 and raised the dividend to $1.56/quarter for 2026. Trading at ~9.5x 2026 EPS vs. UNH's historical 17–20x. Even partial multiple-gap closure on the cleaner book + executed buybacks supports double-digit per-share earnings growth and material total return.

#### Bear Case Risks

1. **Rebate-free model transition compresses 2026–2027 pharmacy profits** — By 2028, Express Scripts will pass through 100% of rebates to clients (currently >95% passed through). Retained rebates are <10% of Evernorth's adjusted pre-tax earnings, but the transition years pose real margin pressure. If the new fee-based model doesn't scale fee revenue commensurately, the segment could under-earn through 2027.

2. **Anthem contract / customer concentration** — The Anthem (Elevance Health) PBM contract is the largest external relationship in US healthcare. Any renegotiation pressure, partial in-sourcing by Anthem, or terms compression would be material. Anthem has historically explored alternatives, including IngenioRx and partnership discussions with other PBMs.

3. **Continued PBM regulatory pressure** — Beyond the FTC settlement, state-level legislation in Texas, Tennessee, and elsewhere mandates PBM transparency / cost-plus pricing. Congress periodically revisits PBM reform. Any nationwide mandate that further constrains revenue models would extend the rebate-free transition pain.

4. **Cigna Healthcare segment remains exposed to medical-cost trend** — Even ex-MA, the commercial Cigna Healthcare division (~$47B revenue, ~$4.5B adj earnings target in 2026) is sensitive to medical-cost inflation, GLP-1 utilization, mental-health utilization, and group commercial pricing cycle. UNH and Elevance commercial-book pressure could spill over.

#### Upcoming Events
- **Q2 2026 earnings**: Late July 2026 — focus on Evernorth growth trajectory, rebate-free transition progress, Anthem commentary
- **2028 rebate-free model rollout milestones**: Watch quarterly client transitions
- **PBM legislation**: State-level mandates and federal proposals through 2026 session
- **Q3 2026 earnings**: Late October 2026
- **2027 Investor Day**: Strategic update on Evernorth Care Group / care services build-out
- **Anthem-Cigna PBM contract**: Periodic renewal / extension milestones

#### Analyst Sentiment
Sell-side consensus has turned more constructive: ~75% Buy / Strong Buy, with multiple Buy upgrades dismissing PBM regulatory fears as overreaction. 12-month price targets cluster around $355–$420 (vs. current trading around $310). The principal divergence is between bulls modeling re-rate to peer multiples on the cleaner book + dovish regulatory outcome, vs. bears modeling continued multiple compression on Evernorth growth deceleration + transition margin pressure.

#### Research Date
Generated: 2026-05-12

## Full Investment Thesis (Premium)

The full research tier adds these thesis-critical dimensions:

- Moat Analysis — durable competitive advantages, switching costs, network effects
- Investment Thesis — variant perception, what has to be true, why market may be wrong
- Bull / Base / Bear Scenarios — probability weights, catalysts, price targets
- Risk Register — macro, competitive, execution, regulatory risks with materiality ratings
- Management Quality — capital allocation track record, incentive alignment
- DCF Valuation — 10-year model with sensitivity matrix

**API endpoint:** GET /api/v1/research/CI/memo

## Navigation

- Overview: /stocks/CI
- Financials: /stocks/CI/financials
- Thesis (this page): /stocks/CI/thesis
- Investment Memo: /stocks/CI/memo
- Coverage universe: /stocks